Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.7% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
26
users have liked this narrative
7
users have commented on this narrative
73
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
35
users have liked this narrative
6
users have commented on this narrative
96
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.6% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
AstraZeneca
NA
NateF
Community Contributor
AZN Market Outlook
AstraZeneca PLC (AZN) is a prominent player in the pharmaceutical industry, with a diverse portfolio and a strong focus on innovation. Has recently demonstrated robust financial performance, with notable developments that may influence its market position over the next 1-3 years.
View narrative
US$130.22
FV
43.5% undervalued
intrinsic discount
6.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 months ago
author updated this narrative
GameStop
YI
yiannisz
Community Contributor
GameStop's Evolution: Navigating Financial Strategies Amidst Market Dynamics
From Brick-and-Mortar to Digital Ventures A favorite among gamers at one point in its history, GameStop has had a very challenging recent past. The transition towards digital distribution of games and competition from online retailers like Amazon has eaten away at its brick and mortar model.
View narrative
US$11.91
FV
87.0% overvalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
2
users have commented on this narrative
8
users have followed this narrative
5 months ago
author updated this narrative
Fiverr International
WA
WallStreetWontons
Community Contributor
Fiverr: Freelancing faces slowing growth despite steps taken into AI
Catalysts Products or Services Impacting Sales and Earnings : Fiverr’s first-quarter 2024 results are expected to show year-over-year revenue growth of 4-6%. Here are some factors contributing to this growth: Complex Services : Fiverr’s expansion into more complex services, such as mobile app development, e-commerce management, and financial consulting, likely boosted profitability during Q1 2024.
View narrative
US$21.45
FV
1.2% overvalued
intrinsic discount
8.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
about 1 year ago
author updated this narrative
Hochschild Mining
RO
RockeTeller
Community Contributor
Silver Play by A Family with 10x Potential
Hochschild Mining – Overview Location : South America Production (2025) : Gold: 250,000 oz Silver: 8 million oz (excluding Pallancata C&M) AISC (Break-even) : Gold: ~$1,850/oz Silver: ~$24/oz Cash Flow Margin at $4,000 gold / $100 silver : Strong Debt : $350M $100M due in 2024 $89M cash on hand $200M additional credit available New & Future Projects Mara Rosa (Brazil) : 80,000 oz/year (low cost) Started in 2024 Royropata (Peru) : 100,000 oz AUEQ (3M oz silver/year) Starts in 2028 Monte Do Carmo (Brazil) : 90,000 oz gold Permitting stage – expected 2028 Volcan (Chile) : 9 million oz gold (.7 gpt) Potential 330K oz/year AISC: ~$1,000 Capex: $900M Production could begin 2028–2030 Not included in cash flow estimate (optional upside or sale) Ownership 50% owned by one family Dividends are a priority Unlikely to sell – growth focus Valuation at $4,000 Gold / $100 Silver Assume production from 2028 with 400K oz gold & 10M oz silver: Gold FCF : 400,000 oz × ($4,000 – $1,850) = $860M Silver FCF : 10,000,000 oz × ($100 – $24) = $760M Total Annual FCF ≈ $1.62B Valuation at 10x FCF = $16.2B Conclusion If Hochschild Mining executes on new projects and gold reaches $4,000/oz, silver hits $100/oz, the company could be worth over $16 billion. However, high debt, permitting risks, and political red flags (Argentina, Peru, Chile) may keep valuation multiples conservative.
View narrative
UK£24.00
FV
87.1% undervalued
intrinsic discount
68.48%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
10
users have commented on this narrative
33
users have followed this narrative
4 months ago
author updated this narrative
QUALCOMM
YI
yiannisz
Community Contributor
Why Qualcomm’s Growth Is Just Starting
Strong Start to FY2025: Record Revenues and EPS Growth Qualcomm (QCOM) started off on a strong note in Fiscal Year 2025 by posting historic revenues of $11.7 billion, up 18% year-on-year (YoY). The company's top-line performance was driven by strong performances by its key business units, led by revenues of $10.1 billion by QCT (Qualcomm CDMA Technologies).
View narrative
US$300.00
FV
50.8% undervalued
intrinsic discount
20.08%
Revenue growth p.a.
Set Fair Value
24
users have liked this narrative
11
users have commented on this narrative
89
users have followed this narrative
5 months ago
author updated this narrative
Banner
WA
WaneInvestmentHouse
Community Contributor
Q1 2025 Earnings Call Highlights: Strong Core Earnings Amid Rising Credit Risks
Release Date: April 17, 2025 Net Profit: $45.1 million or $1.30 per diluted share for Q1 2025. Core Earnings: $59 million for Q1 2025, up from $53 million in Q1 2024.
View narrative
US$47.34
FV
32.0% overvalued
intrinsic discount
7.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 months ago
author updated this narrative
Cidara Therapeutics
BI
birdflustocks
Community Contributor
Cidara Therapeutics: The underestimated potential of CD388
Summary CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.
View narrative
US$100.00
FV
38.0% undervalued
intrinsic discount
83.73%
Revenue growth p.a.
Set Fair Value
9
users have liked this narrative
0
users have commented on this narrative
35
users have followed this narrative
7 months ago
author updated this narrative
Arthur J. Gallagher
LO
London_Investment_Analysts
Community Contributor
Strategic Acquisitions Poised to Drive Share Price Growth
Arthur J. Gallagher & Co. (AJG) has been on an acquisition spree, with significant purchases including AssuredPartners, AnotherDay, Buck, and several others.
View narrative
US$485.74
FV
40.4% undervalued
intrinsic discount
14.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
8 months ago
author updated this narrative
SBC Medical Group Holdings
MR
mrbensonv
Community Contributor
Hidden Gem (NASDAQ: SBC), Empowering the Growth of Aesthetic Medicine
Hidden Gem (NASDAQ: SBC), Empowering the Growth of Aesthetic Medicine SBC Medical Group Holdings ( NASDAQ: SBC ) is making waves in the aesthetic medicine industry with its dynamic growth strategy and robust franchise model. Analysts at Zacks have set a target price of $15.40, reflecting confidence in SBC's ability to scale its operations and expand internationally.
View narrative
US$4.64
FV
5.2% undervalued
intrinsic discount
4.98%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
4
users have commented on this narrative
11
users have followed this narrative
9 months ago
author updated this narrative
Value any company in seconds
Popular companies